Emergent BioSolutions Inc
(FRA:ER4)
€
5.978
0.382 (6.83%)
Market Cap: 319.13 Mil
Enterprise Value: 1.09 Bil
PE Ratio: 0
PB Ratio: 0.51
GF Score: 74/100 - Q1 2024 Emergent BioSolutions Inc Earnings Call TranscriptMay 01, 2024Earnings
- Q4 2023 Emergent BioSolutions Inc Earnings Call TranscriptMar 06, 2024€3.04 (-3.55%)Earnings
- Emergent BioSolutions Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Emergent BioSolutions Inc Earnings Call TranscriptNov 08, 2023€2.22 (+2.58%)Earnings
- Q2 2023 Emergent BioSolutions Inc Earnings Call TranscriptAug 08, 2023€6.66 (+0.60%)Earnings
- Q1 2023 Emergent BioSolutions Inc Earnings Call TranscriptMay 09, 2023€8.26 (+2.48%)Earnings
- Q4 2022 Emergent BioSolutions Inc Earnings Call TranscriptFeb 27, 2023€12.94 (-3.53%)Earnings
- Q3 2022 Emergent BioSolutions Inc Earnings Call TranscriptNov 08, 2022€20.18 (+0.96%)Earnings
- Q2 2022 Emergent BioSolutions Inc Earnings Call TranscriptAug 01, 2022€33.67 (-4.70%)Earnings
- Emergent BioSolutions Inc at Goldman Sachs Leveraged Finance and Credit Conference TranscriptMay 12, 2022
- Emergent BioSolutions Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q1 2022 Emergent BioSolutions Inc Earnings Call TranscriptApr 28, 2022€34.68 (-0.43%)Earnings
- Emergent BioSolutions Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) TranscriptMar 22, 2022
- Q4 2021 Emergent BioSolutions Inc Earnings Call TranscriptFeb 24, 2022€36.49 (-3.85%)Earnings
- Emergent BioSolutions Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Q3 2021 Emergent BioSolutions Inc Earnings Call TranscriptNov 04, 2021€45.25 (+3.38%)Earnings
- Emergent BioSolutions Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Q2 2021 Emergent BioSolutions Inc Earnings Call TranscriptJul 29, 2021€54.82 (+4.30%)Earnings
- Emergent BioSolutions Inc Annual Shareholders Meeting TranscriptMay 20, 2021
- Q1 2021 Emergent BioSolutions Inc Earnings Call TranscriptApr 29, 2021€50.48 (-4.07%)Earnings
- Emergent BioSolutions Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 01, 2021
- Q4 2020 Emergent BioSolutions Inc Earnings Call TranscriptFeb 18, 2021€101Earnings
- Emergent BioSolutions Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Q3 2020 Emergent BioSolutions Inc Earnings Call TranscriptNov 05, 2020€84 (+5.66%)Earnings
- Emergent BioSolutions Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Q2 2020 Emergent BioSolutions Inc Earnings Call TranscriptJul 30, 2020€80 (+2.56%)Earnings
- Emergent BioSolutions Inc Annual Shareholders Meeting TranscriptMay 21, 2020
- Emergent BioSolutions Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 12, 2020
- Q1 2020 Emergent BioSolutions Inc Earnings Call TranscriptApr 30, 2020€68.5 (+0.74%)Earnings
- Q4 2019 Emergent BioSolutions Inc Earnings Call TranscriptFeb 20, 2020€59.5 (+0.85%)Earnings
- Emergent BioSolutions Inc at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Emergent BioSolutions Inc Analyst and Investor Day TranscriptNov 21, 2019
- Q3 2019 Emergent BioSolutions Inc Earnings Call TranscriptNov 06, 2019€52 (+2.97%)Earnings
- Q2 2019 Emergent BioSolutions Inc Earnings Call TranscriptAug 01, 2019€39.65 (-0.92%)Earnings
- Emergent BioSolutions Inc Annual Shareholders Meeting TranscriptMay 23, 2019
- Q1 2019 Emergent BioSolutions Inc Earnings Call TranscriptMay 02, 2019€46.51 (-2.15%)Earnings
- Q4 2018 Emergent BioSolutions Inc Earnings Call TranscriptFeb 21, 2019€57.45 (-0.95%)Earnings
Emergent BioSolutions Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021 / 05:20PM GMT
Release Date Price:
€83.5
(+4.38%)
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Well, welcome, everybody, and thank you for joining our discussion with Emergent BioSolutions. Let's just dive right in since we only have 0.5 hour here.
Questions & Answers
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
There's been a lot of interest in your CDMO business certainly over the last year. And so maybe start with Bob. Can you talk a little bit about the history of the CDMO business, how it came to be the folks of organization? How should investors be thinking about it? Maybe talk a little about some of the backlog and some of the new metrics you've provided for investors to better understand the business. And how should we be thinking about it several years in the future?
Robert G. Kramer
Emergent BioSolutions Inc. - CEO, President & Executive Director
Sure. So first of all, Boris, thanks for the opportunity to participate in the conference. Good to see
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)